Navigation Links
Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain
Date:7/16/2014

SAN FRANCISCO, July 16, 2014 /PRNewswire/ -- Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. With ADYX-003, Adynxx will build on the results of the recently completed ADYX-002 Phase 2 proof-of-concept study.

The 120-patient, placebo-controlled study will evaluate the safety and efficacy of two dose-volume levels of a single administration of AYX1 given prior to unilateral total knee replacement to reduce acute pain with movement and to prevent the transition to persistent pain. The study will follow patients for 42 days with a primary endpoint of pain with walking. Secondary endpoints include pain at rest, pain with knee range of motion, opioid consumption and extent of functional recovery. Further details of the study can be found at www.clinicaltrials.gov.

"In the ADYX-002 proof-of-concept study, AYX1 was well-tolerated and demonstrated a consistent treatment effect across a spectrum of pre-defined movement-evoked pain and range-of-motion assessments. Further, this first efficacy study was very informative regarding the dose-volume relationship that drives the AYX1 treatment effect at its site of action," said Donald Manning, M.D., Ph.D., chief medical officer of Adynxx. "The current ADYX-003 study is designed to leverage these first Phase 2 data to further enhance the scope and magnitude of the AYX1 therapeutic effect." 

"The clinical results to date support Adynxx's approach to the treatment of pain and we are committed to advancing the development of AYX1 as rapidly as possible," added Julien Mamet, Ph.D., founder and chief scientific officer of Adynxx. "Given the lack of effective treatment options for movement-evoked pain after surgery, we believe AYX1 has the potential to transform the therapeutic paradigm by preventing pain for the millions of patients who undergo surgery every year."

About Adynxx

Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes.  Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery. Funded by Domain Associates, Adynxx has successfully completed a safety Phase 1 and a proof-of-concept phase 2 clinical study of AYX1.  Additional AYX drug candidate compounds designed to address a range of intractable neuropathic and inflammatory pain syndromes are also in active development.

For more information please visit www.adynxx.com.

Corporate Contact
William Martin
Director, Operations
(415) 512-7740
wmartin@adynxx.com

Media Contacts
David Schull
Matt Middleman, M.D.
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Adynxx
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1
2. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
3. Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
4. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
5. Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
6. MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome
7. Tandem Diabetes Care Initiates Voluntary Recall for Specific Lots of Insulin Cartridges Used with t:slim Insulin Pump
8. Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine
9. Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
10. Cameron Associates Initiates Coverage of Brainsway, Ltd.
11. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for Healthcare ... Hospital on April 5-7. The series is a multi-day, multi-workshop event designed to ... cover a broad range of topics, including coaching skills, the scientific method of ...
(Date:2/12/2016)... ... 12, 2016 , ... The Jones Agency, a family owned insurance company with ... a cooperative charity drive with the Tarrant Area Food Bank in the hopes of ... families in need, the Tarrant County Food Bank offers hope and security to the ...
(Date:2/12/2016)... ... 2016 , ... Miami Dental Specialists is excited to bring patients the choice ... in January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic ... be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, ... Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health ... therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 ...
Breaking Medicine News(10 mins):